Summary: For the first three months of 2009 the Pharmexa Group generated revenues of DKK 4.1 million and a net loss of DKK 12.7 million. Research and development costs totalled DKK 10.5 million. On May 5, 2009 Pharmexa's shareholders approved the proposed combination with the Norwegian biotech company Affitech AS. The enlarged company expects a net loss for 2009 of DKK 45-50 million. Pharmexa's previously announced expectations was a net loss in 2009 of approximately DKK 25 million, based on Pharmexa as a standalone company.